MRNS vs. IFRX, SCYX, MNOV, DERM, TPST, HOOK, JAGX, RLYB, CELU, and LPTX
Should you be buying Marinus Pharmaceuticals stock or one of its competitors? The main competitors of Marinus Pharmaceuticals include InflaRx (IFRX), SCYNEXIS (SCYX), MediciNova (MNOV), Journey Medical (DERM), Tempest Therapeutics (TPST), Hookipa Pharma (HOOK), Jaguar Health (JAGX), Rallybio (RLYB), Celularity (CELU), and Leap Therapeutics (LPTX). These companies are all part of the "pharmaceutical preparations" industry.
InflaRx (NASDAQ:IFRX) and Marinus Pharmaceuticals (NASDAQ:MRNS) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, community ranking, dividends, media sentiment, valuation, profitability, institutional ownership, risk and analyst recommendations.
Marinus Pharmaceuticals received 193 more outperform votes than InflaRx when rated by MarketBeat users. Likewise, 69.27% of users gave Marinus Pharmaceuticals an outperform vote while only 64.19% of users gave InflaRx an outperform vote.
InflaRx currently has a consensus target price of $13.50, suggesting a potential upside of 728.22%. Marinus Pharmaceuticals has a consensus target price of $13.79, suggesting a potential upside of 936.52%. Given InflaRx's higher possible upside, analysts plainly believe Marinus Pharmaceuticals is more favorable than InflaRx.
42.4% of InflaRx shares are held by institutional investors. Comparatively, 98.8% of Marinus Pharmaceuticals shares are held by institutional investors. 16.3% of InflaRx shares are held by insiders. Comparatively, 5.5% of Marinus Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
In the previous week, Marinus Pharmaceuticals had 5 more articles in the media than InflaRx. MarketBeat recorded 10 mentions for Marinus Pharmaceuticals and 5 mentions for InflaRx. Marinus Pharmaceuticals' average media sentiment score of 0.94 beat InflaRx's score of -0.13 indicating that InflaRx is being referred to more favorably in the media.
InflaRx has a net margin of 0.00% compared to InflaRx's net margin of -513.80%. Marinus Pharmaceuticals' return on equity of -37.37% beat InflaRx's return on equity.
InflaRx has a beta of 1.26, meaning that its stock price is 26% more volatile than the S&P 500. Comparatively, Marinus Pharmaceuticals has a beta of 1.14, meaning that its stock price is 14% more volatile than the S&P 500.
InflaRx has higher earnings, but lower revenue than Marinus Pharmaceuticals. InflaRx is trading at a lower price-to-earnings ratio than Marinus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
InflaRx beats Marinus Pharmaceuticals on 11 of the 19 factors compared between the two stocks.
Get Marinus Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for MRNS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MRNS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Marinus Pharmaceuticals Competitors List
Related Companies and Tools
